Consegna Group (ASX: CGP) is ready to start negotiating licences for the commercialisation of the company’s BreatheAssist device.
The company has completed the final phase of product development on time and under budget.
“We are very pleased to announce that activity at our manufacturing partner, APS Innovations, has resulted in this finished product,” Consegna managing director Fabio Pannuti said.
“Our confidence about the commercial scale manufacturability and the establishment of a clinical utility has allowed us to move forward with our commercialisation plans.”
BreatheAssist is a multi-functional nasal dilation technology that enhanced nasal airflow by 37% in a clinical study.
Importantly, there are multiple licensing opportunities for BreatheAssist, including sport, medication delivery, snoring cessation, aiding sleep apnoea and the filtration of pollen and other airborne pollutants.
While final patents have been granted in major global markets, Pannuti said the company would initially focus on the sporting industry.
“Although there are several applications for BreatheAssist, it is clear the most immediate path to cash flow is through the sports market. Other markets and licensing transactions will be addressed during the first two quarters of next year.”
Consegna is preparing to undertake trials in a number of sports disciplines in Australia and overseas.
Originally published at: http://www.proactiveinvestors.com.au/companies/news/22714/consegna-group-ready-to-commercialise-breatheassist-22714.html
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment